Anca Copaescu

Director at BioMarin Pharmaceutical, Inc.

Anca Copaescu

Anca Copaescu

Director at BioMarin Pharmaceutical, Inc.

Overview
RelSci Relationships

330

Contact Data
Trying to get in touch with Anca Copaescu? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
View Relationship Details
RelSci Relationships are individuals Anca Copaescu likely has professional access to. A relationship does not necessarily indicate a personal connection.
Jean-Jacques Bienaimé

Chief Executive Officer & President at BioMarin Pharmaceutical, Inc.

Relationship likelihood: Strong

G. Eric Davis

Executive Vice President, General Counsel & Secretary at BioMarin Pharmaceutical, Inc.

Relationship likelihood: Strong

Brian R. Mueller

Executive Vice President & Chief Financial Officer at BioMarin Pharmaceutical, Inc.

Relationship likelihood: Average

Cheri L Plungy

Executive Director at BioMarin Pharmaceutical, Inc.

Relationship likelihood: Average

Gordon Sun

Executive Director at BioMarin Pharmaceutical, Inc.

Relationship likelihood: Average

Jeff Ajer

Executive Vice President & Chief Commercial Officer at BioMarin Pharmaceutical, Inc.

Relationship likelihood: Average

Eduardo E. Von Pervieux

Chief Information Officer at BioMarin Pharmaceutical, Inc.

Relationship likelihood: Average

Philip Lo Scalzo

Senior Vice President, Chief Compliance Officer at BioMarin Pharmaceutical, Inc.

Relationship likelihood: Average

Lon Cardon

Chief Scientific Strategy Officer at BioMarin Pharmaceutical, Inc.

Relationship likelihood: Average

Henry J. Fuchs

Chief Medical Officer & Executive Vice President at BioMarin Pharmaceutical, Inc.

Relationship likelihood: Average

Reveal deeper insights into your organization's relationships
with RelSci Contact Aggregator.

Empower Your Business Applications with Industry-Leading
Relationship Data from the RelSci API.

Get Contact Information on the
World's Most Influential Decision Makers.

Discover the Power of Your Network with
RelSci Premium Products.
In The News
PR Newswire
December 15, 2020
Sponsors Create Proposal Requests Faster With Clinical Maestro; Advancement Leverages CRO Collaboration to Speed Design and Planning for Clinical Trials
PR Newswire
October 13, 2020
Strategikon Launches Two New Business Operation Services To Provide Fast Relief For Intense Clinical Budget Season; New Services for the CLINICAL MAESTRO Platform Leverage Technology to Speed Planning, Budgeting, and Outsourcing Output with Greater Accura
PR Newswire
August 18, 2020
Clinical Maestro Grows Team to Handle Demand for Outsourcing Improvements; Clinical trial Sponsors seek increased outsourcing efficiency and accuracy to cope with pandemic-induced change.
PR Newswire
June 10, 2020
Clinical Maestro adds LEAD Module to Modernize Accrual and Reforecasting Process for Clinical Trials; Clinical trial Sponsors improve tracking of actual expenses and enhance forecasting and contract deviation analyses.
PR Newswire
January 14, 2019
Clinical Maestro adds eProcurement and CRO Edition to Clinical Trial Business Software Suite
Trending People
Patrick Vallance
UK doctors seek review of 12-week gap between vaccine doses - Associated Press
Henry L. "Hank" Aaron
Home run king Aaron dies at 86THE QUOTE - South Florida Sun-Sentinel
Charles E. Schumer
February date set for Trump trialPelosi to send article of impeachment to Senate... - South Florida Sun-Sentinel
Jennifer Rene Psaki
Signing orders, urging more helpBiden offers some aid and asks Congress for bigg... - South Florida Sun-Sentinel
Boris Johnson
Rotting fish, lost business and piles of red tape. The reality of Brexit hits Br... - CNN
Trending People
Patrick Vallance
UK doctors seek review of 12-week gap between vaccine doses - Associated Press
Henry L. "Hank" Aaron
Home run king Aaron dies at 86THE QUOTE - South Florida Sun-Sentinel
Charles E. Schumer
February date set for Trump trialPelosi to send article of impeachment to Senate... - South Florida Sun-Sentinel
Jennifer Rene Psaki
Signing orders, urging more helpBiden offers some aid and asks Congress for bigg... - South Florida Sun-Sentinel
Boris Johnson
Rotting fish, lost business and piles of red tape. The reality of Brexit hits Br... - CNN
Paths to Anca Copaescu
Potential Connections via
Relationship Science
You
Anca Copaescu
Director at BioMarin Pharmaceutical, Inc.
Career History
Director
Tenure Unconfirmed
BioMarin Pharmaceutical, Inc.

About BioMarin BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; KUVAN® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, and BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers and BMN-111, a modified C-natriuretic peptide, which is currently in Phase I clinical development for the treatment of achondroplasia.

Other Affiliations

Anca Copaescu is affiliated with BioMarin Pharmaceutical, Inc.

Stay informed and up-to-date on your network with RelSci news and business alerting service. Nurture your network and further your business goals with smart intelligence on the people and companies that matter most to you.

Browse in-depth profiles on 12 million influential people and organizations. Find RelSci relationships, employment history, board memberships, donations, awards, and more.

Explore notable alumni from top universities and organizations. Expand your fundraising pool and make warm introductions to potential new business connections.

Harness the power of your relationships with RelSci Pro, the powerful platform for identifying relationship-driven business opportunities and connections that can propel your career forward.

Stay informed and up-to-date on your network with RelSci news and business alerting service. Nurture your network and further your business goals with smart intelligence on the people and companies that matter most to you.

Browse in-depth profiles on 12 million influential people and organizations. Find RelSci relationships, employment history, board memberships, donations, awards, and more.

Explore notable alumni from top universities and organizations. Expand your fundraising pool and make warm introductions to potential new business connections.

Harness the power of your relationships with RelSci Pro, the powerful platform for identifying relationship-driven business opportunities and connections that can propel your career forward.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Anca Copaescu. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Anca Copaescu's profile does not indicate a business or promotional relationship of any kind between RelSci and Anca Copaescu.